Uniphar PLC — Declaration of Voting Results & Voting Rights Announcements 2026

May 7, 2026

National Storage Mechanism | Additional information

RNS Number : 4755D

Uniphar PLC

07 May 2026

AGM Results

Dublin, London | 7 May 2026

Uniphar plc (the Company) announces that at its Annual General Meeting ("AGM") held at 11.00 a.m. today, 7 May 2026, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment, with the exception of Resolution 7 which was not passed.

Details of votes cast are set out below:

	RESOLUTION	For	For %	Against	Against %	Withheld
1	Financial Statements and Reports	155,801,328	100.00%	-	0.00%	65,198
2	Final Dividend of €3.4m	155,862,330	100.00%	4,196	0.00%	-
3(a)	Re-elect Ger Rabbette	155,170,281	99.57%	662,597	0.43%	33,648
3(b)	Re-elect Tim Dolphin	155,132,752	99.55%	700,126	0.45%	33,648
3(c)	Re-elect Paul Hogan	154,475,082	99.11%	1,391,444	0.89%	-
3(d)	Re-elect Sue Webb	153,396,166	98.44%	2,436,712	1.56%	33,648
3(e)	Re-elect Jim Gaul	143,860,681	92.32%	11,972,197	7.68%	33,648
3(f)	Re-elect Liz Hoctor	155,516,769	99.78%	349,757	0.22%	-
3(g)	Re-elect Maurice Pratt	149,269,506	95.78%	6,569,125	4.22%	-
3(h)	Re-elect Valerie Sick	154,441,434	99.11%	1,391,444	0.89%	33,648
4	Remuneration of Auditors	132,756,119	85.17%	23,109,607	14.83%	800
5	Authority to allot relevant securities	125,718,359	80.66%	30,148,167	19.34%	-
6	Disapplication of pre- emption rights in specified circumstances	155,282,158	99.63%	583,568	0.37%	800
7	Disapplication of pre- emption rights in additional Circumstances*	103,983,762	66.71%	51,882,764	33.29%	-
8	Authorise market purchases of the Company's Ordinary Shares	155,455,359	100.00%	-	0.00%	411,167
9	Re-issuance of Treasury Shares	155,866,526	100.00%	-	0.00%	-

*The Board notes that Resolution 7, relating to the dis-application of pre-emption rights in certain additional circumstances, was not passed at the AGM. Resolution 7 was proposed on terms consistent with the Statement of Principles on Disapplying Pre-emption Rights published by the Pre-emption Group in November 2022 (the "Statement of Principles") and the Directors believe that this resolution is appropriate in order to maintain flexibility to allot additional securities within the circumstances contemplated by the terms of the resolution and the Statement of Principles. In accordance with provision 4 of the UK Corporate Governance Code (the "Code"), the Board confirms that it will engage with shareholders to understand and discuss the reasons behind the votes received against this resolution. An update on the views received from shareholders and actions taken will be provided within six months of the Annual General Meeting, in accordance with the Code.

--- ENDS ---

Contact details

Uniphar Group	Tel: +353 (0) 1 428 7777
Allan Smylie, Head of Strategy and IR
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)	Tel: +353 (0) 1 679 6363
Daragh O'Reilly Niall Gilchrist Ivan Murphy
RBC Capital Markets (Joint Corporate Broker)	Tel: +44 (0) 20 7653 4000
Jamil Miah Daniel Saveski
Stifel Nicolaus Europe Limited (Joint Corporate Broker)	Tel: +44 (0) 20 7710 7600
Matt Blawat Ben Maddison Francis North
Q4 PR	Tel: +353 (0) 1 475 1444
Iarla Mongey, Public Relations Advisor to Uniphar Group

About Uniphar plc 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGAKOBDNBKDFPK